1. Lee JM, Ahn SH, Kim HS, Park H, Chang HY, Kim do Y, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011;53:1486-1493. 21520167.
2. Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepat 2005;12:333-345. 15985003.
3. Yuen MF, Kato T, Mizokami M, Chan AO, Yuen JC, Yuan HJ, et al. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 2003;39:850-855. 14568270.
4. Liaw YF. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol 2002;17(Suppl 3):S333-S337. 12472959.
9. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514. 19280622.
10. Chon YE, Kim SU, Lee CK, Heo J, Kim JK, Yoon KT, et al. Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B. Antivir Ther 2011;16:469-477. 21685534.
11. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-143. 20955704.
12. Song BC, Cui XJ, Kim H. Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection. Intervirology 2005;48:133-137. 15812186.
14. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. 16391218.
15. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686. 16530509.
16. Buti M, Homs M. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Expert Rev Gastroenterol Hepatol 2012;6:413-421. 22928893.
18. Ceylan B, Yardimci C, Fincanci M, Eren G, Tozalgan U, Muderrisoglu C, et al. Comparison of tenofovir and entecavir in patients with chronic HBV infection. Eur Rev Med Pharmacol Sci 2013;17:2467-2473. 24089225.
20. Miquel M, Nunez O, Trapero-Marugan M, Diaz-Sanchez A, Jimenez M, Arenas J, et al. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Ann Hepatol 2013;12:205-212. 23396731.
21. Dusheiko G, Antonakopoulos N. Current treatment of hepatitis B. Gut 2008;57:105-124. 17502343.
22. van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002;36:507-508. 12143063.
24. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-559. 10702206.
25. Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, et al. Japan HBV Genotype Research Group. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Hepatology 2001;33:218-223. 11124839.